542 results about "Chalcone" patented technology

Disclosed is a composition comprising at least two of the following ingredients: Magnolia extract, honokiol, humulus lupulus extract, hesperidin methyl chalcone, gotu kola, dipeptide valyl-tryptophane, palmitoyl tetrapeptide-3, corylus avellana bud extract, centella asiatica extract, cucumis sativa extract, morus alba extract, hibiscus sabdariffa flower extract, vitis vinifera extract, ascorbyl glucoside, citrus medica limonum extract, avena sativa kernel extract, hydrolyzed soy protein, aniseed myrtle extract, tasmania lanceolata leaf extract, artemisia abrotanum extract, or citrus grandis fruit extract or any combination thereof. Also disclosed are methods of treating skin conditions by topically applying the composition to skin.

The present invention features composition comprising a chalcone and the use thereof for treating acne and reducing the appearance of oil or pores on the skin, hair and scalp.

Provided herein are methods and compositions for treating or preventing metabolic disorders, such as obesity and diabetes. Methods may comprise modulating the activity or level of a sirtuin, such as SIRTl or Sir2. Exemplary methods comprise contacting a cell with a sirtuin activating compound, such as a flavone, stilbene, flavanone, isoflavone, catechin, chalcone, tannin or anthocyanidin, or an inhibitory compound, such as nicotinamide.

The invention discloses a novel 2-hydroxyl chalcone compound (I), as well as pharmacy acceptable salt, preparation method, medical composition, and purpose thereof in preparing medicines for treating and/or preventing neurodegenerative diseases including but not limited to vascular dementia, Alzheimer's diseases, Parkinson's diseases, Huntington's diseases, dementia relevant to HIV, multiple sclerosis, amyotrophic lateral sclerosis, neuropathic pain, glaucoma and the like (As shown in the description.).

Disclosed is a Sofalcone preparation method which mainly comprises, (1) subjecting p-hydroxybenzaldehyde and 2,4-ihydroxyacetophenone to condensation reaction under alkaline condition, obtaining 2,4,4-Trihydro-xychalcone, (2) subjecting 2,4,4-trihydro-xychalcone and 1-bromo-3-methyl-2-butene to condensation reaction, obtaining 2-hydroxyl-4,4-bis (3-methyl-2-butenyloxy) chalcone, (3) subjecting the 2-hydroxyl-4,4-bis (3-methyl-2-butenyloxy) chalcone and ethyl bromoacetate to condensation under the action of potasium carbonate, thus obtaining sofalcone. The mol ratio of p-hydroxybenzaldehyde, 2.4-dihydroxyacetophenone, 1-bromo-3-methyl-2-butene, and ethyl bromoacetate can be 1 : (0.90-1.50) : (1.60-2.55) : (0.60-1.25).

The invention discloses an aryl-substituted chalcones compound, a preparation method and an application. The aryl-substituted chalcones compound has a structure shown as a formula(I) or a formula(II), wherein, R1, R2, R3, R4, R5 are aromatic groups or aromatic groups with a substituent, the aromatic groups are phenyl, furan, thienyl, pyridyl, pyrimidyl, thiazolyl or pyrrolyl, the substituent is one or more selected from hydroxyl, methoxyl, ethoxyl, methyl, ethyl, trifluoromethyl, halogen, amino, methylamino or dimethylamino; R3 is selected from hydrogen, amino or-NHCOCH3. The aryl-substituted chalcones compound introduces the aromatic groups based on a phenyl skeleton to form a structure with steric hindrance, the molecule presents a V-shaped spatial conformation, compared with the current chalcone compounds, and the aryl-substituted chalcones compound has higher inhibitory activity to cancer cells and can be used for preparing the antitumor drugs.

The formulation includes a combination of a chalcone, specifically, methylhydroxychalcone polymer, in the amount of 6 mg to 24 mg, and chromium, in the amount of 500 mcg to 2000 mcg. The formulation also includes a plurality of vitamins and nutrients, vitamins B₆, C, E and K including green tea polyphenols and other nutrients.

The invention discloses a method for extracting and refining hydroxysafflor yellow A from safflower. The hydroxysafflor yellow A is a compound with a chalcone monoside structure, and is abundant in traditional Chinese medicinal material safflower (CARTHAMI FLOS). The hydroxysafflor yellow A with content of over 80 percent is obtained through the following five steps of: extracting form the traditional Chinese medicine safflower; purifying through ion exchange resin; purifying through neutral polarity macro-porous adsorption resin; purifying through non-polar macro-porous adsorption resin; and freeze-drying, wherein the transfer rate is over 20 percent.

The invention discloses novel a chalcone compound extracted and purified from Oxytropis falcate, a preparation method and an application thereof. Identified through a spectral method, the novel chalcone compound has the structural formula C15H1203 and is named 2', 4'-dihydroxy chalcone, and the preparation method combines column chromatography and preparative liquid purification method. Result from experiments in vitro shows that the novel chalcone compound can remarkably restrain the growth and proliferation of tumor cells and has good efficacy of restraining acute inflammation of mice and chronic inflammation of rats. Therefore, the novel chalcone compound is expected to be developed to be a new generation of antitumor drugs or anti-inflammatory drugs.

The invention belongs to the field of pharmaceutical chemistry, and specifically relates to an application of specific chalcone compounds in the preparations of inflammation resisting medicines and medicines used for treating inflammation-related diseases. With the chalcone compounds, expression and release of various inflammatory factors such as TNF-alpha, IL-6, COX-2, IL-1beta and IL-12 can be inhibited; nuclear translocation of an inflammation-regulation-related nuclear factor -kappaB can be substantially inhibited; and phosphorylation of inflammation signal pathways ERK and p38 can be inhibited. As a result of in-vivo experiments, with the compounds, the survival rate of LPS-introduced mice mortality can be substantially improved.

The invention discloses a novel carbamate chalcone compound represented by a formula I shown in the description and pharmaceutically acceptable salts thereof, a preparation method for the novel carbamate chalcone compound and the pharmaceutically acceptable salts thereof, a pharmaceutical composition and use of the pharmaceutical composition in the preparation of drugs for treating and/or preventing neurodegenerative related diseases, including, but not limited to neurodegenerative diseases such as vascular dementia, Alzheimer's disease, Parkinson's disease, Huntington's disease, HIV related cretinism, multiple sclerosis, progressive lateral spinal sclerosis, neuropathic pain and glaucoma.

The present invention relates generally to compounds providing antibacterial therapeutic agents and preparations, and related methods of using and making antibacterial compounds. Antibacterial compounds of the present invention include chalcone, alkylpyrimidine, aminopyrimidine and cyanopyridine compounds and derivatives thereof exhibiting minimum inhibitory concentrations (MIC) similar to or less than conventional antibacterial compounds in wide use.

The present invention has an object to provide an agent for strengthening calcium-containing tissues, which can be safely applied; and its use: The present invention solves the object by providing an agent for strengthening calcium-containing tissues, which comprises one or more flavones, flavonols, flavanones, flavanonols, anthocyanidins, flavanols, chalcones, and aurones.

The present invention relates to the compounds of the general formula (I), a composition for and a method of treating breast cancer or other proliferative disorders in a subject using a compound of general formula [I],

wherein the substituents are as defined in the specification.

The invention relates a method of the synthesis of chalcone and derivatives thereof by using ionic liquid. Benzaldehyde and acetophenone are used as reactants and the molar ratio of the benzaldehyde and the acetophenone is 1:1 to 5:1; the ionic liquid is used as a catalyst and solvent and the mass of the ionic liquid added takes up 1:20 to 10:1 of the total mass of the reactants; the reaction pressure is normal pressure, the reaction temperature is 80 to 200 DEG C and the reaction time is 0.5 to 1.2 hours; the ionic liquid is composed of an alkyl imidazole cation or a pyridine cation functionalized by sulfonic group and inorganic or organic anions. The ionic liquid used by the invention is stable in the air and the water, is provided with an ignorable vapor pressure and is non volatile, which is an environment friendly catalyst and reaction solvent. The chalcone (or the derivatives of the invention ) of the reaction products of the ionic liquid can automatically be layered with the ionic liquid, which leads separation process to be easier and the ionic liquid can be used repeatedly by being dried in vacuum with the temperature of 110 DEG C for 1 to 6 hours after the reactions.

The present disclosure provides Diels-Alder adducts of chalcone and prenylphenyl moieties capable of modulating the activity of cannabinoid receptors, and to oligomers of flavan-3-ol capable of modulating fat absorption and storage. Such Diels-Alder adducts of chalcone and prenylphenyl moieties or oligomers of flavan-3-ol can optionally be used in combination with other weight management agents, such as anorectic agents, a lipase inhibitors, other cannabinoid receptor modulators, psychotropic agents, insulin sensitizers, stimulants, or satiety agents, as well as to methods of use thereof such as treating or preventing weight gain or obesity, promoting weight loss, appetite suppression, modifying satiety, or the like.

The invention discloses a fragrant microcapsule for composite cigarettes.A nucleus of the microcapsule is prepared from novel methyl hesperidin dihydro chalcone, rhodinol and rhodinol-beta-D-glucopyranoside.A shell of the microcapsule is prepared from chitosan.The invention further discloses a preparation method of the fragrant microcapsule for composite cigarettes and application for increasing fragrance of cigarettes.The fragrant microcapsule for composite cigarettes can keep cigarette fragrance stability, durability and uniformity consistency of fragrance release along with time.

The present invention relates generally to compounds providing antibacterial therapeutic agents and preparations, and related methods of using and making antibacterial compounds. Antibacterial compounds of the present invention include chalcone, alkylpyrimidine, aminopyrimidine and cyanopyridine compounds and derivatives thereof exhibiting minimum inhibitory concentrations (MIC) similar to or less than conventional antibacterial compounds in wide use. For example, the present invention provides chalcone and cyanopyridine compounds, and derivatives thereof, exhibiting high antibacterial activities having multiple electron withdrawing group substituents, such as halogens and fluorinated alky groups, and optionally having hydroxyl and/or alkoxyl groups substituents.

The invention provides a Michael addition product of ferrocene-based chalcone and ethyl acetoacetate and a preparation method thereof. The preparation method comprises the steps: adding A mol of ferrocene-based chalcone and B mol of ethyl acetoacetate into a dry reaction container, adding an alkaline substance as a catalyst, and grinding until the raw materials are subjected to complete reaction, wherein the ratio of A to B is 1:1; washing the product obtained from the reaction with water, carrying out suction filtration, recrystallizing the filter cake, and thus obtaining the Michael addition product of ferrocene-based chalcone and ethyl acetoacetate. The preparation method has the advantages of simple operation, short reaction time, mild reaction conditions, and low equipment requirements, the reaction is carried out only with grinding, at the same time, the catalyst is cheap and easy to get, the yield of the obtained product is up to 91.3% or more, the purity is high, and the preparation method is a green, simple and fast method for preparation of the Michael addition product of ferrocene-based chalcone and ethyl acetoacetate.

The present invention refers to the technical field of flavone component extraction, and provides an extraction separation method of a flavone component based on amination graphene. The flavone components comprise flavones, flavanols, isoflavones, flavanones, flavanonols, flavanones, anthocyanidins, chalcones, and chromones etc. The extraction separation method is adsorption extraction, and amination graphene is taken as a medium of adsorption extraction. The extraction separation method of the flavone components based on amination graphene is superior in separation speed and product purity, low cost and convenient operation.

The invention relates to the field of tea preparation, in particular to a preparation technology of ashitaba tea. The established preparation method of the ashitaba tea comprises the steps of separate leaf-stem treatment, gradient low temperature baking, intermittent kneading and forming, and short-time high-temperature perfuming. All stem and leaf tissues of whole ashitaba are taken as raw materials, and treated separately, so that phenomena such as excessive loss of chalcone, a nonuniform drying degree, and burning of leaves due to excessive baking are avoided; the prepared product is uniform in baking degree and good in sense organ character; a chalcone content and a vitamin C content are higher than tea products stir-fried only by the leaves under conventional technological conditions on the basis that the perfume of the ashitaba tea is ensured due to the gradient low temperature baking, the intermittent kneading and forming, and the short-time high-temperature perfuming; the nutritive and health-care effects of the ashitaba tea are ensured.

The invention discloses a quinoid chalcone compound with an isopentenyl group at an A ring, and a preparation method and anti-inflammatory activity thereof. The compound has a structure as shown in a general formula (I) which is described in the specification. The preparation method comprises the following steps: (1) synthesizing 3,5-dihydroxy-2-acetyl-6,6-diisopentenylcyclohexyl-2,4-dienone; (2) synthesizing 3-hydroxy-5-methoxy-2-acetyl-6,6-diisopentenylcyclohexyl-2,4-dienone; (3) synthesizing a methoxy group protected quinoid chalcone compound with the isopentenyl group at the A ring; and (4) synthesizing the quinoid chalcone compound with the isopentenyl group at the A ring. The compound is simple to prepare and has obvious anti-inflammatory action.